Supplementary materials

Physiologically based pharmacokinetic modeling of nanoceria systemic distribution in rats suggests dose- and route-dependent biokinetics

Ulrika Carlander¹, Tshepo Paulsen Moto², Anteneh Assefa Desalegn¹, Robert A. Yokel³ and Gunnar Johanson¹

¹ Karolinska Institutet, Institute of Environmental Medicine, Unit of Work Environment Toxicology

² University of Pretoria, Faculty of Health Sciences, School of Health Systems and Public Health

³ University of Kentucky, Department of Pharmaceutical Sciences

Correspondence: Ulrika Carlander Box 210, SE-171 77 Stockholm, Sweden Tel +46 733248834

Email: ulrika.carlanderswetox.se

Link to supplementary information: https://ki.box.com/s/exiu59ri25lihwzhk08fy5gxa93b1tmq

Contents

Abbreviations	3
Nanoparticle-independent physiologically based pharmacokincetic (PBPK) model parameters Table S1. Summary of nanoparticle-independent PBPK model parameters. ^a	4 4
Sensitivity analysis	5
Table S2. Relative sensitivity coefficient for 5 nm at 10 h (85 mg/kg)	5
Table S3. Relative sensitivity coefficient for 5 nm at 30 days (end of exposure, 85 mg/kg)	6
Table S4. Relative sensitivity coefficient for 5 nm at 10 h (11 mg/kg)	0
Table S5. Relative sensitivity coefficient for 5 nm at 30 days (end of exposure 11 mg/kg)	، ع
Table S6. Relative sensitivity coefficients for 30 nm at 10 h (87 mg/kg)	۵
Table S0. Relative sensitivity coefficients for 30 nm at 90 d (end of experiment, 87 mg/kg)	10
Calibration 5 nm	11
Figure S1. Observed versus simulated concentrations in tissues.	11
Comparison of the 5 nm calibrated PBPK model to independent data set with 3 nm nanoceria	12
Figure S2. Observed versus simulated concentrations in blood	12
Comparison of the 30 nm calibrated PBPK model to independent data sets with nanoceria around 30 nm	13
Figure S3. Observed versus simulated concentrations in tissues (Yokel et al. 2013)	13
Figure S4. Observed versus simulated concentrations in tissues (Yokel et al. 2014)	14
Figure S5. Observed versus simulated concentrations in blood (Dan et al. 2012)	15
Figure S6. Observed versus simulated concentrations in tissues (Yokel et al. 2009 – 50 mg/kg)	16
Figure S7. Observed versus simulated concentrations in tissues (Yokel et al. 2009 – 250 mg/kg)	17
Figure S8. Observed versus simulated concentrations in tissues (Yokel et al. 2009 – 750 mg/kg)	18
Figure S9. Observed versus simulated concentrations in tissues (Konduru et al. 2015 – Silica coated CeO ₂)	19
Figure S10. Observed versus simulated concentrations in tissues (Konduru et al. 2015 – CeO ₂)	20
Comparison of the 5 nm calibrated PBPK to independent data sets with 15 nm ceria	21
Figure S11. Observed versus simulated concentrations in tissues following administration of 15 nm ceria	21
Comparison of the 5 nm calibrated PBPK to independent data sets with 55 nm ceria	22
Figure S12. Observed versus simulated concentrations in tissues for 55 nm ceria.	22
Tissue: liver concentration ratios	23
Figure S13. Blood:liver concentration ratios	23
Figure S14. Spleen:liver concentration ratios.	24
Figure S15. Brain:liver concentration ratios	25
Calibration oral administration	26
Figure S16. Observed versus simulated concentrations in feces (Kumari et al. 2014)	26
Figure S17. Observed versus simulated concentrations in tissues (He et al. 2010)	27
Figure S18. Observed versus simulated concentrations in tissues (Park et al. 2009)	28
Figure S19. Observed versus simulated concentrations in tissues (Park et al. 2009)	29
Calibration inhalation	30
Figure S20. Observed versus simulated concentrations in tissues (Li et al. 2016– Pristine)	30
Figure S21. Observed versus simulated concentrations in tissues (Li et al. 2016 – Aged)	31
Figure S22. Observed versus simulated concentrations in tissues (Li et al. 2016 – Aged)	32
Calibration <i>it</i> instillation	33
Figure S23. Observed versus simulated concentrations in tissues (He et al. 2010)	33
References	34

Abbreviations

AUC	area under the curve
BW	body weight
CeO ₂	cerium dioxide
CL _f	clearance rate constant to feces
CL _u	clearance rate constant to urine
fBI _{tissue}	fraction of tissue volume that is blood
fQ _{tissue}	fraction of cardiac output to tissue
fRBI _{brain}	residual fraction of brain blood after harvesting
fRBI _{tissue}	residual fraction of tissue blood after harvesting
fW _{tissue}	tissue weight, fraction of body weight
it	intratracheally
iv	intravenously
k _{ab0}	uptake rate constant to phagocytic cells
k _{sab0}	uptake rate constant to phagocytic cells in spleen
M_{cap}	maximum uptake capacity per phagocytic cell
n _{cap in tissue}	number of phagocytizing cells per gram tissue
Р	partition coefficient between blood and tissue
РВРК	physiologically based pharmacokinetic
R ²	coefficient of determination
X _{brain}	permeability coefficient from blood to brain.
X _{fast}	permeability coefficient from blood to liver, spleen, and bone marrow
X _{rest}	permeability coefficient from blood to lung, kidney, heart, and carcass

Nanoparticle-independent physiologically based pharmacokincetic (PBPK) model parameters

 Table S1. Summary of nanoparticle-independent PBPK model parameters.^a

Parameter (unit)	Description	Blood	Bone Marrow	Brain	Heart	Kidney	Liver	Lung	Other	Spleen
fQ _{tissue} (unitless)	Fraction of cardiac output to tissue	-	0.0267	0.02	0.051	0.141	0.183	1	$1-\Sigma fQ_{tissue}$	0.0146
fW _{tissue} (unitless) ^b	Tissue weight, fraction of body weight	0.074	0.03	0.006	0.003	0.007	0.034	0.005	$1-\Sigma fW_{tissue}$	0.002
fBl _{tissue} (unitless) ^b	Fraction of tissue volume that is blood	0.2 Arterial 0.8 Venous	0.1	0.03	0.26	0.16	0.21	0.36	0.04	0.22
fRBI _{tissue} (unitless) ^c	Residual fraction of tissue blood after harvesting	-	0.177	0.346	0.177	0.177	0.177	0.177	0.177	0.177

^a Parameter values from Li et al.¹

Sensitivity analysis

		Rono							Othor			
ALIC 10 h	Blood	marrow	Brain	Fores	Heart	Kidnev	livor	lung	tissues	PC	Soleen	Ilrino
Body weight	1 13	1 02	1 07	0.06	1 11	1 11	1 02	1 06	0.86	0.96	1 07	0.09
Dose rate	1 90	0.38	1.85	1 47	1.82	1.11	0.45	0.93	1 66	0.71	1 44	1 65
Exposure duration	1.88	0.33	1.82	1.32	1.79	1.78	0.40	0.91	1.58	0.64	1.36	1.57
CL _f	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
CL.	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00
k _{ab0}	-0.12	0.04	-0.13	-0.20	-0.12	-0.12	0.15	-0.05	-0.15	0.05	-0.14	-0.16
k _{sab0}	-0.07	-0.01	-0.06	-0.03	-0.06	-0.06	-0.01	-0.03	-0.05	0.02	0.76	-0.05
k _{de}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
M _{can}	-0.89	0.62	-0.84	-0.47	-0.81	-0.79	0.54	0.07	-0.66	0.29	-0.44	-0.64
n _{cap in blood}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in bone marrow}	-0.31	0.72	-0.30	-0.18	-0.30	-0.29	-0.06	-0.15	-0.24	0.10	-0.21	-0.24
n _{cap in brain}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in heart}	0.00	0.00	0.00	0.00	0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in kidney}	0.00	0.00	0.00	0.00	0.00	0.04	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in liver}	-0.56	-0.09	-0.52	-0.28	-0.52	-0.52	0.60	-0.27	-0.40	0.18	-0.34	-0.39
n _{cap in lung}	-0.01	0.00	-0.01	-0.01	-0.01	-0.01	0.00	0.50	-0.01	0.00	-0.01	-0.01
n _{cap in other tissues}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in spleen}	-0.01	0.00	-0.01	0.00	-0.01	-0.01	0.00	-0.01	-0.01	0.00	0.12	-0.01
Р	-0.28	0.13	-0.29	0.61	0.55	0.59	0.18	0.28	-0.33	0.00	0.55	-0.34
X _{brain}	0.00	0.00	0.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
X _{fast}	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	-0.01	0.00	0.01	-0.01
X _{rest}	-0.51	-0.08	-0.47	-0.22	-0.43	-0.44	-0.09	-0.24	0.58	0.15	-0.30	-0.34
fBlood _{art}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{bone marrow}	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{brain}	0.00	0.00	0.78	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{heart}	0.00	0.00	0.00	0.00	0.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{kidney}	0.00	0.00	0.00	0.00	0.00	0.07	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{liver}	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00
fblood _{lung}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.07	0.00	0.00	0.00	0.00
fblood _{other tissues}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05	0.00	0.00	0.00
fblood _{spleen}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fQ _{bone marrow}	0.02	0.02	0.02	0.00	0.02	0.02	0.00	0.01	-0.04	-0.01	0.01	0.01
fQ _{brain}	0.02	0.00	0.23	0.01	0.02	0.02	0.00	0.01	-0.02	-0.01	0.01	0.01
fQ _{heart}	0.05	0.01	0.04	0.02	0.08	0.04	0.01	0.02	-0.05	-0.01	0.03	0.03
fQ _{kidney}	0.13	0.02	0.12	0.05	0.12	0.15	0.02	0.06	-0.15	-0.04	0.07	0.08
fQ _{spleen}	0.01	0.00	0.01	0.01	0.01	0.01	0.00	0.01	-0.02	0.00	0.03	0.01
fQ _{liver}	0.16	0.03	0.15	0.09	0.15	0.15	0.03	0.08	-0.20	-0.05	0.09	0.11
fRBI _{brain}	0.00	0.00	0.78	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fRBI _{tissue}	0.00	0.01	0.00	0.00	0.10	0.07	0.01	0.07	0.05	0.00	0.00	0.00
fW _{blood}	0.80	-0.07	-0.22	-0.38	-0.21	-0.21	-0.10	-0.11	-0.31	-0.15	-0.27	-0.31
fW _{bone marrow}	-0.36	0.91	-0.35	-0.27	-0.35	-0.34	-0.08	-0.18	-0.32	0.08	-0.27	-0.31
fW _{brain}	0.00	0.00	0.78	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
t W _{heart}	0.00	0.00	0.00	0.00	0.96	0.00	0.00	0.00	0.00	0.00	0.00	0.00
tW _{kidney}	-0.01	0.00	-0.01	-0.01	-0.01	0.96	0.00	0.00	-0.01	0.00	-0.01	-0.01
TVV _{liver}	-0.70	-0.13	-0.67	-0.51	-0.66	-0.66	0.84	-0.34	-0.58	0.19	-0.50	-0.58
TVV _{lung}	-0.02	0.00	-0.02	-0.02	-0.02	-0.02	0.00	0.98	-0.02	0.00	-0.01	-0.02
I VV _{spleen}	-0.08	-0.01	-0.08	-0.04	-0.08	-0.08	-0.02	-0.04	-0.06	0.02	0.93	-0.06

		Bono							Othor			
ALLC 20 days	Blood	DUILE	Brain	Facas	Hoort	Kidnov	Livor	Lung	tissues	DC	Splaan	Urino
Body weight	1 21	1 02	0.97	0.21		1 07	1.03	1 01	0.96	1 00	1 16	0.21
Dose rate	1.21	0.06	1 78	1.80	0.69	0.57	0.10	0.05	1 78	0.99	1.10	1 78
Exposure duration	1.50	0.00	1 78	1.80	0.69	0.57	0.10	0.05	1.70	0.99	1 31	1 78
CL _f	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
CL.	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00
k _{ab0}	-0.12	0.08	-0.09	-0.09	-0.05	-0.04	0.10	0.02	-0.08	0.00	-0.08	-0.09
k _{sab0}	-0.05	0.00	-0.07	-0.07	-0.02	-0.02	0.00	0.00	-0.07	0.00	0.71	-0.07
k _{de}	0.19	-0.10	0.15	0.15	0.08	0.07	-0.16	-0.02	0.14	0.00	-0.24	0.15
M _{can}	-0.58	0.94	-0.77	-0.79	0.32	0.43	0.90	0.95	-0.78	0.00	-0.32	-0.78
n _{cap in blood}	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in bone marrow}	-0.20	0.90	-0.25	-0.26	-0.09	-0.07	0.01	0.00	-0.26	0.00	-0.18	-0.26
n _{cap in brain}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in heart}	0.00	0.00	0.00	0.00	0.57	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in kidney}	0.00	0.00	0.00	0.00	0.00	0.64	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in liver}	-0.37	0.04	-0.49	-0.50	-0.16	-0.13	0.89	0.01	-0.49	0.00	-0.34	-0.49
n _{cap in lung}	-0.01	0.00	-0.01	-0.01	0.00	0.00	0.00	0.94	-0.01	0.00	-0.01	-0.01
n _{cap in other tissues}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in spleen}	-0.02	0.00	-0.02	-0.02	-0.01	-0.01	0.00	0.00	-0.02	0.00	0.21	-0.02
Р	-0.17	0.09	-0.17	0.83	0.31	0.27	0.11	0.04	-0.15	0.00	0.62	-0.17
X _{brain}	0.00	0.00	0.96	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
X _{fast}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00
X _{rest}	-0.80	-0.09	-0.81	-0.82	-0.35	-0.29	-0.11	-0.05	0.16	0.01	-0.63	-0.81
fBlood _{art}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{bone marrow}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{brain}	0.00	0.00	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{heart}	0.00	0.00	0.00	0.00	0.05	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{kidney}	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{liver}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{lung}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{other tissues}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{spleen}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fQ _{bone marrow}	0.04	0.00	0.04	0.04	0.02	0.01	0.01	0.00	-0.01	0.00	0.03	0.04
fQ _{brain}	0.03	0.00	0.99	0.03	0.01	0.01	0.00	0.00	-0.01	0.00	0.02	0.03
fQ _{heart}	0.07	0.01	0.07	0.07	0.03	0.03	0.01	0.00	-0.01	0.00	0.06	0.07
fQ _{kidney}	0.20	0.02	0.21	0.21	0.09	0.07	0.03	0.01	-0.04	0.00	0.16	0.21
fQ _{spleen}	0.02	0.00	0.02	0.02	0.01	0.01	0.00	0.00	0.00	0.00	0.03	0.02
fQ _{liver}	0.26	0.03	0.27	0.27	0.11	0.10	0.04	0.02	-0.05	0.00	0.21	0.27
fRBI _{brain}	0.00	0.00	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fRBI _{tissue}	0.00	0.00	0.00	0.00	0.05	0.02	0.00	0.00	0.00	0.00	0.00	0.00
tW _{blood}	1.00	0.00	-0.01	-0.01	0.00	0.00	0.00	0.00	-0.01	0.00	0.00	-0.01
tW _{bone marrow}	-0.23	1.01	-0.28	-0.28	-0.10	-0.08	0.00	0.00	-0.28	0.00	-0.20	-0.28
TVV _{brain}	0.00	0.00	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
I VV _{heart}	0.00	0.00	0.00	0.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
f vv kidney	0.00	0.00		0.00	0.00	1.00	1.00	0.00	0.00	0.00	0.00	
f\//	-0.44	0.02	-0.55	-0.57	-0.13	-0.10	1.01	1 00	-0.55	0.00	-0.39	-0.55
fW _{enloon}	-0.01	0.00	-0.01	-0.01	-0.00	-0.00	0.00	0.00	-0.01	0.00	0.01	-0.01
spieeri	0.07	0.00	5.05	0.05	5.05	0.00	5.50	5.50	0.05	5.50	0.55	5.05

Table S3. Relative sensitivity coefficient for 5 nm at 30 days (end of exposure, 85 mg/kg)

		Bone							Other			
AUC 10 h	Blood	marrow	Brain	Feces	Heart	Kidney	Liver	Lung	tissues	PC	Spleen	Urine
Body weight	1.06	0.99	1.00	0.04	1.03	1.02	1.04	1.01	0.82	1.00	1.05	0.05
Dose rate	1.10	0.99	1.10	1.08	0.72	0.63	1.01	0.54	1.09	0.99	1.09	1.09
Exposure duration	1.10	0.93	1.09	0.97	0.71	0.63	0.95	0.49	1.04	0.93	1.03	1.03
CL _f	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
CL _u	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00
k _{ab0}	-0.73	0.07	-0.71	-0.64	-0.46	-0.41	0.24	0.05	-0.65	0.08	-0.65	-0.66
k _{sab0}	-0.02	-0.02	-0.02	-0.02	-0.02	-0.01	-0.02	-0.01	-0.02	0.00	0.91	-0.02
k _{de}	0.01	0.00	0.01	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
M _{cap}	-0.10	0.01	-0.10	-0.08	0.28	0.37	-0.01	0.45	-0.09	0.01	-0.08	-0.09
n _{cap in blood}	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in brain}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in bone marrow}	-0.04	0.07	-0.04	-0.03	-0.02	-0.02	-0.03	-0.01	-0.03	0.00	-0.03	-0.03
n _{cap in heart}	0.00	0.00	0.00	0.00	0.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in kidney}	0.00	0.00	0.00	0.00	0.00	0.43	0.00	0.00	0.00	0.00	0.00	0.00
n _{can in liver}	-0.05	-0.04	-0.04	-0.04	-0.03	-0.03	0.04	-0.02	-0.04	0.00	-0.04	-0.04
n _{can in lung}	-0.02	-0.02	-0.02	-0.02	-0.01	-0.01	-0.02	0.49	-0.02	0.00	-0.02	-0.02
n _{can} in other tissues	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{can in snleen}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00
P	-0.75	0.04	-0.74	0.29	0.05	0.06	0.22	0.06	-0.70	0.05	0.25	-0.70
r X ₁	0.00	0.00	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
X frank	-0.06	0.08	-0.06	-0.03	-0.04	-0.04	-0.03	-0.03	-0.06	0.00	-0.04	-0.06
X .	-0.13	-0.11	-0.13	-0.11	-0.04	-0.03	-0.11	0.03	0.82	0.01	-0.12	-0.12
fRlood	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fhlood	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fhlood	0.00	0.00	0.75	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fhlood	0.00	0.00	0.00	0.00	0.07	0.00	0.00	0.02	0.00	0.00	0.00	0.00
fblood	0.00	0.00	0.00	0.00	0.00	0.04	0.00	0.02	0.00	0.02	0.00	0.00
fblood.	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood.	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00		0.00	0.00
fblood	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
for the spleen	-0.00	0.00 ' 0.16	0.00	· _0.00	0.00		0.00	0.00	-0.00	0.00	007	0.00
fQ _{bone marrow}	0.07	0.10	-0.07	-0.0,	0.0-	-0.0-	-0.00	0.0-	-0.03	0.01	-0.07	0.07
TQ _{brain}	0.00	0.00	0.23	0.00	0.00	0.00	0.00	0.00	20.0- RO D	0.00	0.00	0.00
TQ _{heart}	0.01	0.03	0.01	0.01	0.03	0.01	0.01	0.01	-0.00	0.00	0.01	0.01
fQ _{kidney}	0.03	0.03	0.03	0.05	0.02	0.00	0.05	0.01	-0.21		0.03	0.05
fQ _{liver}	0.02	0.02	0.02	0.00	0.01	0.01	0.00	0.01	-0.29	0.00	0.02	0.02
fQ _{spleen}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.02	0.00	0.03	0.00
fKBI _{brain}	0.00		0.75	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00
TRBI _{tissue}	1.00	0.00	0.00	0.00	0.07	0.04	0.00	0.01	0.05	0.00	0.00	0.00
tW _{blood}	1.00	-0.07	-0.02	-0.14	-0.01	-0.01	-0.07	-0.05	-0.00	-0.07	-0.07	-0.07
tW _{bone marrow}	-0.29	0.54	-0.28	-0.24	0.10	-0.10	-0.24	-0.13	-U.20	0.02	-0.20	-U.20
†W _{brain}	0.00	0.00	0.75	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fW _{heart}	0.00	0.00	0.00	0.00	0.95	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fW _{kidney}	0.00	0.00	0.00	-0.01	0.00	0.95	0.00	0.00	-0.01	0.00	0.00	0.00
fW _{liver}	-0.51	-0.43	-0.50	-0.49	-0.33	-0.29	0.52	-0.23	-0.48	0.04	-0.47	-0.47
fW _{lung}	-0.03	-0.03	-0.03	-0.03	-0.02	-0.02	-0.03	0.90	-0.03	0.00	-0.03	-0.03
fW _{spleen}	-0.02	0.02	-0.02	-0.02	-0.02	-0.01	-0.02	-0.01	-0.02	. 0.00	0.95	-0.02

Table S4. Relative sensitivity coefficient for 5 nm at 10 h (11 mg/kg)

		Bone							Other			
AUC 720 h	Blood	marrow	Brain	Feces	Heart	Kidney	Liver	Lung	tissues	PC	Spleen	Urine
Body weight	1.05	1.02	0.83	0.05	1.00	1.00	1.05	1.02	0.82	1.00	1.06	0.06
Dose rate	0.90	0.97	1.13	1.14	0.06	0.06	1.01	0.40	1.14	1.00	1.13	1.14
Exposure duration	0.90	0.96	1.12	1.14	0.06	0.06	1.01	0.40	1.14	1.00	1.13	1.14
CL _f	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
CL _u	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00
k _{ab0}	-0.55	0.10	-0.71	-0.75	-0.02	-0.01	0.22	0.08	-0.70	0.00	-0.71	-0.72
k _{sab0}	-0.02	-0.02	-0.02	-0.02	0.00	0.00	-0.02	-0.01	-0.02	0.00	0.94	-0.02
k _{de}	0.33	-0.03	0.28	0.29	0.01	0.01	-0.07	-0.09	0.28	0.00	-0.06	0.28
M _{cap}	0.10	0.03	-0.12	-0.14	0.94	0.94	-0.01	0.60	-0.14	0.00	-0.13	-0.14
n _{cap in blood}	0.22	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in brain}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in bone marrow}	-0.05	0.10	-0.05	-0.05	0.00	0.00	-0.05	-0.02	-0.05	0.00	-0.06	-0.05
n _{cap in heart}	0.00	0.00	0.00	0.00	0.94	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in kidney}	0.00	0.00	0.00	0.00	0.00	0.95	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in liver}	-0.05	-0.05	-0.06	-0.06	0.00	0.00	0.06	-0.02	-0.06	0.00	-0.06	-0.06
n _{cap in lung}	-0.02	-0.02	-0.02	-0.02	0.00	0.00	-0.02	0.64	-0.02	0.00	-0.02	-0.02
n _{cap in other tissues}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in spleen}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00
P	-0.57	0.08	-0.73	0.22	0.01	0.01	0.20	0.07	-0.73	0.00	0.23	-0.74
X _{brain}	0.00	0.00	0.94	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
X _{fact}	-0.02	0.05	-0.04	-0.02	0.00	0.00	-0.02	-0.01	-0.04	0.00	-0.03	-0.04
Xract	-0.17	-0.16	-0.18	-0.18	-0.01	-0.01	-0.17	-0.05	0.80	0.00	-0.19	-0.18
fBlood	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fbloodhone marrow	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood	0.00	0.00	0.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fQhono marrow	-0.02	0.10	-0.04	-0.04	0.00	0.00	-0.03	-0.01	-0.09	0.00	-0.04	-0.04
fQhrain	0.01	0.01	0.95	0.01	0.00	0.00	0.01	0.00	-0.03	0.00	0.01	0.01
fO _{boot}	0.02	0.02	0.02	0.02	0.00	0.00	0.02	0.01	-0.07	0.00	0.02	0.02
fO _{Lideo} ,	0.04	0.04	0.05	0.05	0.00	0.00	0.04	0.02	-0.20	0.00	0.05	0.05
fO	0.05	0.04	0.05	0.07	0.00	0.00	0.07	0.02	-0.27	0.00	0.05	0.05
fO	0.00	0.00	0.00	0.01	0.00	0.00	0.01	0.00	-0.02	0.00	0.02	0.00
fRBL	0.00	0.00	0.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fRRI	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
f\\/	1 00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
f\/.	-0.26	0.59	-0.31	-0.32	-0.02	-0.02	-0.28	-0.12	-0.32	0.00	-0.32	-0.32
f\Λ/.	0.20	0.00	0.01	0.00	0.02	0.02	0.20	0.12	0.02	0.00	0.02	0.00
f\//.	0.00	0.00	0.00	0.00	1 00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
f v heart	0.00	0.00	0.00	0.00	0.00	1 00	0.00	0.00	0.00	0.00	0.00	0.00
f VV kidney	-0.00		0.00	0.00	0.00		0.00	0.00	-0.50	0.00	-0.00	0.00
fvv	0.30	-0.42	0.00	0.03	0.03	0.02	0.03	-0.17	0.00	0.00	-0.45	0.00
TVV _{lung} f\Λ/	-0.02	-0.05	-0.03	-0.03	0.00	0.00	-0.03	0.57	-0.05	0.00	-0.05	-0.05
¹ v ^v spleen	-0.02	-0.02	-0.02	-0.02	0.00	0.00	-0.02	-0.01	-0.02	0.00	0.90	-0.02

Table S5. Relative sensitivit	y coefficient for 5 nm at 30 day	vs (end of exposure,	11 mg/kg)
		Je (ena el expectale,	

		Bone							Other			
AUC 10 h	Blood	marrow	Brain	Feces	Heart	Kidney	Liver	Lung	tissues	PC	Spleen	Urine
Body weight	1.03	1.01	1.03	0.01	1.00	1.00	1.01	1.01	0.86	0.97	1.01	0.02
Dose rate	1.24	0.61	1.24	1.07	1.18	1.16	0.80	0.61	1.18	0.73	0.81	1.14
Exposure duration	1.21	0.55	1.21	0.91	1.14	1.12	0.73	0.57	1.11	0.66	0.74	1.05
CL _f	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
CL _u	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00
k _{ab0}	-0.25	0.29	-0.25	-0.17	-0.23	-0.23	0.43	-0.08	-0.21	0.28	-0.14	-0.21
k _{sab0}	-0.07	-0.03	-0.07	-0.04	-0.07	-0.07	-0.04	-0.03	-0.06	0.08	0.65	-0.06
k _{de}	0.01	0.00	0.00	0.00	0.00	0.00	-0.01	0.00	0.00	-0.01	-0.01	0.00
M _{cap}	-0.24	0.38	-0.24	-0.07	-0.17	-0.15	0.20	0.39	-0.18	0.26	0.18	-0.14
n _{cap in blood}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in bone marrow}	-0.10	0.42	-0.10	-0.03	-0.09	-0.09	-0.04	-0.05	-0.08	0.11	-0.04	-0.06
n _{cap in brain}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in heart}	0.00	0.00	0.00	0.00	0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in kidney}	0.00	0.00	0.00	0.00	0.00	0.05	0.00	0.00	0.00	0.00	0.00	0.00
N _{cap in liver}	-0.10	-0.03	-0.10	-0.03	-0.09	-0.08	0.26	-0.05	-0.07	0.11	-0.04	-0.06
N _{cap in lung}	-0.01	0.00	-0.01	0.00	-0.01	-0.01	0.00	0.49	-0.01	0.01	0.00	-0.01
n _{cap in other tissues}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in spleen}	-0.03	-0.01	-0.03	-0.01	-0.03	-0.03	-0.01	-0.01	-0.02	0.04	0.27	-0.02
P	-0.37	0.34	-0.37	0.73	0.17	0.27	0.44	0.11	-0.33	0.31	0.48	-0.32
X _{brain}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
X _{fast}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
X _{rest}	-0.10	-0.04	-0.10	-0.04	0.00	-0.01	-0.05	-0.03	0.57	0.10	-0.05	-0.07
fBlood _{art}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{bone marrow}	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{brain}	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{heart}	0.00	0.00	0.00	0.00	0.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{kidney}	0.00	0.00	0.00	0.00	0.00	0.25	0.00	0.00	0.00	0.00	0.00	0.00
fblood _{liver}	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.00	0.00	0.00	0.00	0.00
fblood _{lung}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.19	0.00	0.00	0.00	0.00
fblood _{other tissues}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.35	0.00	0.00	0.00
fblood _{spleen}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00
fQ _{soleen}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.02	0.00	0.01	0.00
fQ _{liver}	0.03	0.01	0.03	0.02	0.03	0.03	0.02	0.01	-0.19	-0.03	0.01	0.02
fQ _{brain}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.02	0.00	0.00	0.00
fQ _{heart}	0.01	0.00	0.01	0.00	0.09	0.01	0.00	0.00	-0.05	-0.01	0.00	0.01
fQ _{kidney}	0.02	0.01	0.02	0.01	0.02	0.10	0.01	0.01	-0.14	-0.03	0.01	0.02
fQ _{hone marrow}	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	-0.03	0.00	0.00	0.00
fRBI _{brain}	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fRBI _{tissue}	0.00	0.02	0.00	0.00	0.35	0.25	0.04	0.19	0.35	0.00	0.01	0.00
fW _{blood}	0.48	-0.33	-0.52	-0.68	-0.52	-0.51	-0.43	-0.27	-0.61	-0.41	-0.45	-0.61
fW _{bone marrow}	-0.20	0.91	-0.20	-0.12	-0.18	-0.18	-0.11	-0.09	-0.18	0.18	-0.11	-0.15
fW _{brain}	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fW _{heart}	0.00	0.00	0.00	0.00	0.91	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fW _{kidnev}	0.00	0.00	0.00	0.00	0.00	0.91	0.00	0.00	-0.01	0.00	0.00	0.00
fWlung	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	0.97	-0.01	0.01	-0.01	-0.01
fW _{liver}	-0.29	-0.12	-0.29	-0.16	-0.27	-0.26	0.84	-0.14	-0.26	0.28	-0.15	-0.22
fW _{spleen}	-0.11	-0.04	-0.11	-0.05	-0.10	-0.09	-0.05	-0.05	-0.09	0.11	0.94	-0.07

Table S6. Relative sensitivit	v coefficients for	30 nm at 10 h	(87 ma/ka)
	,	••••••••	(•······

		Bone							Other			
AUC 90 days	Blood	marrow	Brain	Feces	Heart	Kidney	Lung	Liver	tissues	PC	Spleen	Urine
Body weight	1.19	1.07	1.13	0.18	1.08	1.06	1.03	1.09	0.94	1.00	1.10	0.18
Dose rate	1.27	0.23	1.32	1.49	0.53	0.41	0.10	0.35	1.47	0.99	0.40	1.49
Exposure duration	1.27	0.23	1.32	1.49	0.53	0.41	0.10	0.35	1.47	0.99	0.40	1.49
CL _f	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
CL _u	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00
k _{ab0}	-0.20	0.27	-0.20	-0.20	-0.08	-0.06	0.09	0.35	-0.16	0.01	-0.09	-0.20
k _{sab0}	-0.05	-0.01	-0.05	-0.06	-0.02	-0.02	0.00	-0.01	-0.06	0.00	0.46	-0.06
k _{de}	0.27	-0.29	0.27	0.28	0.11	0.09	-0.08	-0.38	0.24	-0.01	-0.41	0.28
M _{cap}	-0.27	0.76	-0.32	-0.48	0.47	0.59	0.90	0.64	-0.47	0.01	0.59	-0.48
n _{cap in blood}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in bone marrow}	-0.09	0.68	-0.11	-0.15	-0.04	-0.03	0.01	0.02	-0.15	0.00	0.02	-0.15
n _{cap in brain}	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in heart}	0.00	0.00	0.00	0.00	0.58	0.00	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in kidney}	0.00	0.00	0.00	0.00	0.00	0.67	0.00	0.00	0.00	0.00	0.00	0.00
n _{cap in liver}	-0.12	0.06	-0.15	-0.23	-0.05	-0.04	0.02	0.61	-0.23	0.00	0.05	-0.23
n _{cap in lung}	-0.01	0.00	-0.01	-0.01	0.00	0.00	0.86	0.00	-0.01	0.00	0.00	-0.01
n _{can in other tissues}	-0.01	-0.01	-0.01	0.00	0.00	0.00	0.00	-0.01	0.00	0.00	-0.01	0.00
n _{cap in spleen}	-0.05	0.03	-0.06	-0.09	-0.02	-0.01	0.01	0.02	-0.09	0.00	0.54	-0.09
P	-0.26	0.27	-0.26	0.72	0.17	0.16	0.10	0.34	-0.23	0.00	0.37	-0.27
X _{brain}	0.00	0.00	0.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Xfact	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Xrast	-0.72	-0.28	-0.71	-0.69	-0.30	-0.23	-0.12	-0.36	0.26	0.01	-0.38	-0.69
fBloodage	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fbloodhana marrow	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood	0.00	0.00	0.77	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fblood	0.00	0.00	0.00	0.00	0.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fhlood	0.00	0.00	0.00	0.00	0.00	0.08	0.00	0.00	0.00	0.00	0.00	0.00
fhlood	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fhlood	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00
fblood	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fhlood	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
fo .	0.02	0.01	0.02	0.02	0.00	0.01	0.00	0.00	-0.01	0.00	0.01	0.00
fO	0.02	0.02	0.02	0.02	0.01	0.01	0.00	0.01	-0.08	0.00	0.01	0.02
fO.	0.2	0.05	0.20	0.23	0.10	0.00	0.01	0.12	-0.01	0.00	0.12	0.20
fO.	0.05	0.01	0.23	0.05	0.01	0.01	0.00	0.01	-0.01	0.00	0.01	0.02
f Q _{heart}	0.07	0.03	0.00	0.00	0.00	0.02	0.01	0.00	-0.02	0.00	0.03	0.00
f C	0.10	0.07	0.10	0.17	0.00	0.00	0.05	0.05	-0.00	0.00	0.10	0.17
fppl	0.05	0.01	0.05	0.03	0.01	0.01	0.01	0.02	0.01	0.00	0.02	0.05
	0.00	0.00	0.77	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	0.00	0.00	0.00	0.00	0.14	0.00	0.01	0.00	0.00	0.00	0.00	0.00
f vv _{blood}	0.99	1 01	-0.01	-0.05	0.00	0.00	0.01	0.02	-0.03	0.01	0.01	-0.03
f VV bone marrow	0.14	1.01	-0.10	-0.21	-0.00	-0.05	0.00	0.00	0.21	0.00	-0.01	0.21
TVV _{brain}	0.00	0.00	0.70	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
TVV _{heart}	0.00	0.00	0.00	0.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
fW _{kidney}	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
fW _{lung}	-0.01	0.00	-0.01	-0.01	0.00	0.00	1.00	0.00	-0.01	0.00	0.00	-0.01
fW _{liver}	-0.23	0.04	-0.26	-0.36	-0.10	-0.07	0.02	1.02	-0.36	0.00	0.01	-0.36
TW _{spleen}	-0.10	0.02	-0.11	-0.15	-0.04	-0.03	0.01	0.01	-0.15	0.00	1.01	-0.15

Table S7. Relative sensitivity coefficients for 30 nm at 90 d (end of experiment, 87 mg/kg)

Calibration 5 nm

Α



Figure S1. Observed versus simulated concentrations in tissues.

PBPK model calibration of 5 nm ceria. (A) Compares logs of simulated and observed mean concentration in different tissues of rats at various time-points, following 1 h *iv* infusion of 85 mg/kg body weight.² (B) Comparison of logs of simulated and observed mean concentration in different tissues of rats, 30 days after 1 h *iv* infusion of 11 mg/kg body weight.³

Comparison of the 5 nm calibrated PBPK model to independent data set with 3 nm nanoceria



Figure S2. Observed versus simulated concentrations in blood.

Comparison of the 5 nm calibrated PBPK model against independent data set with 3-nm ceria. Simulated (solid curve) and observed (symbols) time courses of the nanoceria concentration in blood following an *iv* bolus dose of 10 mg/kg body weight.⁴

Comparison of the 30 nm calibrated PBPK model to independent data sets with nanoceria around 30 nm



Figure S3. Observed versus simulated concentrations in tissues (Yokel et al. 2013)

Comparison of the 30 nm calibrated PBPK model against independent data set with 30 nm ceria. (A) Simulated (solid curves) and observed (symbols) time courses of the nanoceria concentration in different tissues following *iv* infusion of 85 mg/kg body weight during 1 h.²





Comparison of the 30 nm calibrated PBPK model against independent data set with 30 nm ceria. Simulated (solid curves) and observed (symbols) time courses of the nanoceria concentration in different tissues following *iv* infusion of 6 mg/kg body weight during 1 h.³



Figure S5. Observed versus simulated concentrations in blood (Dan et al. 2012)

Comparison of the 30 nm calibrated PBPK model against independent data set with 30 nm ceria. Simulated (solid curves) and observed (symbols) time courses of the nanoceria concentration in blood following *iv* infusion of 85 mg/kg body weight during 1 h.⁵



Figure S6. Observed versus simulated concentrations in tissues (Yokel et al. 2009 – 50 mg/kg)

Comparison of the 30 nm calibrated PBPK model against independent data sets with 30 nm ceria. Simulated (solid curves) and observed (symbols) time courses of the nanoceria concentration in different tissues following *iv* infusion of 50 mg/kg during 0.5 h.⁶



Figure S7. Observed versus simulated concentrations in tissues (Yokel *et al.* 2009 – 250 mg/kg)

Comparison of the 30 nm calibrated PBPK model against independent data set with 30 nm ceria. (A-D) Simulated (solid curves) and observed (symbols) time courses of the nanoceria concentration in different tissues following *iv* infusion of 250 mg/kg during 2.5 h.⁶



Figure S8. Observed versus simulated concentrations in tissues (Yokel *et al.* 2009 – 750 mg/kg)

Comparison of the 30 nm calibrated PBPK model against independent data set with 30 nm ceria. Simulated (solid curves) and observed (symbols) time courses of the nanoceria concentration in different tissues following *iv* infusion of 750 mg/kg during 7.5 h. 6



Figure S9. Observed versus simulated concentrations in tissues (Konduru *et al.* 2015 – Silica coated CeO₂)

Comparison of the 30 nm calibrated PBPK model against independent data set with 30 nm ceria. Simulated (solid curves) and observed (symbols) time courses of the nanoceria concentration in different tissues following an *iv* bolus dose of 1 mg/kg body weight.⁷



Figure S10. Observed versus simulated concentrations in tissues (Konduru et al. 2015 – CeO₂)

Comparison of the 30 nm calibrated PBPK model against independent data set with 30 nm nanoceria. Simulated (solid curves) and observed (symbols) time courses of the nanoceria concentration in different tissues following an iv bolus dose of 1 mg/kg body weight.⁷

Comparison of the 5 nm calibrated PBPK to independent data sets with 15 nm ceria



Figure S11. Observed versus simulated concentrations in tissues following administration of 15 nm ceria.

Comparison of the 5 nm calibrated PBPK model against independent data sets with 15 nm ceria. (A-E) Simulated (solid curve) and observed (symbols) time courses of the 15 nm ceria concentration following 1 h *iv* infusion of 70 mg/kg body weight.(A-D)² (E)⁵ (F) Comparison of logs of simulated and observed mean concentration in different tissues. The line of unity (solid) represents a perfect match and the regression line (\mathbb{R}^2 , dashed) describes the outcome.

Comparison of the 5 nm calibrated PBPK to independent data sets with 55 nm ceria





Comparison of the 5 nm calibrated PBPK model against independent data sets with 55 nm ceria.(A-E) Simulated (solid curves) and observed (symbols) time courses of the 55 nm ceria concentration following 1 h *iv* infusion of 50 or 100 mg/kg body weight.(A-D)² (E)⁵ (F) Comparison of logs of simulated and observed mean concentration in different tissues. The line of unity (solid) represents a perfect match and the regression line (R², dashed) describes the outcome.



Tissue: liver concentration ratios

Figure S13. Blood:liver concentration ratios.

Time courses for blood:liver concentration ratios for (A) *iv* administered 5 nm ceria,^{2,3,8} (B) *iv* administered 30 nm ceria,^{2,3,6,7,9} (C) inhaled nanoceria,^{10,11} (D) *it* instilled nanoceria,^{12,13} and (E - F) orally administered nanoceria.¹²⁻¹⁶



Figure S14. Spleen:liver concentration ratios.

Time courses for spleen:liver concentration ratios for (A) *iv* administered 5 nm ceria, 2,3,8 (B) *iv* administered 30 nm ceria, 2,3,6,7,9 (C) inhaled nanoceria, 10,11 (D) *it* instilled nanoceria, 12,13 and (E -F) orally administered nanoceria. $^{12-17}$



Figure S15. Brain:liver concentration ratios.

Plot of time courses for brain:liver concentration ratios for (A) *iv* administered 5 nm ceria, ^{2,3,8} (B) *iv* administered 30 nm ceria, ^{2,3,6,7,9} (C) inhaled nanoceria, ^{10,11} (D) *it* instilled nanoceria, ^{12,13} and (E - F) orally administered nanoceria. ¹²⁻¹⁷

Calibration oral administration



Figure S16. Observed versus simulated concentrations in feces (Kumari et al. 2014)

Calibration of the PBPK model against independent data sets with nanoceria was not performed because levels recovered in excretion were only a fraction of the administered dose. Figure presents the time courses of the fraction of the administered dose observed in feces following oral doses of 100, 500 and 1000 mg/kg.¹⁵



Figure S17. Observed versus simulated concentrations in tissues (He et al. 2010)

Calibration of the PBPK model against independent data sets with nanoceria. (A-E) Simulated (solid curves) and observed (symbols) time courses of the nanoceria concentration in different tissues following an oral dose of 5 mg/kg.¹²





Calibration of the PBPK model against independent data sets with nanoceria. (A-C) Simulated (solid curves) and observed (symbols) time courses of the nanoceria concentration in different tissues following an oral dose of 5000 mg/kg.¹⁷



Figure S19. Observed versus simulated concentrations in tissues (Park et al. 2009)

Calibration of the PBPK model against independent data sets with nanoceria. (A-C) Simulated (solid curves) and observed (symbols) time courses of the nanoceria concentration in different tissues following an oral dose of 100 mg/kg.¹⁷

Calibration inhalation





Calibration of the PBPK model against independent data sets with unaged (pristine) nanoceria. (A-D) Simulated (solid curves) and observed (symbols) time courses of the nanoceria concentration in different tissues following 6 h nose only inhalation, air concentration 0.6 mg/m³.¹⁰





Calibration of the PBPK model against independent data sets with aged nanoceria. (A-E) Simulated (solid curves) and observed (symbols) time courses of the nanoceria concentration in different tissues following 4 h nose only inhalation, air concentration 0.4 mg/m³.¹⁰





Calibration of the PBPK model against independent data sets with aged nanoceria. (A-E) Simulated (solid curves) and observed (symbols) time courses of the nanoceria concentration in different tissues following 4 h nose only inhalation, air concentration 0.5 mg/m³.¹⁰

Calibration it instillation



Figure S23. Observed versus simulated concentrations in tissues (He et al. 2010)

Calibration of the PBPK model against independent data sets with nanoceria. (A-E) Simulated (solid curves) and observed (symbols) time courses of the nanoceria concentration in different tissues following *it* instillation of 1 mg.¹²

References

- 1. Li D, Johanson G, Emond C, Carlander U, Philbert M, Jolliet O. Physiologically based pharmacokinetic modeling of polyethylene glycol-coated polyacrylamide nanoparticles in rats. *Nanotoxicology*. Jan 6 2014;8(S1):128–137.
- **2.** Yokel RA, Tseng MT, Dan M, et al. Biodistribution and biopersistence of ceria engineered nanomaterials: size dependence. *Nanomedicine*. Apr 2013;9(3):398-407.
- **3.** Yokel RA, Unrine JM, Wu P, Wang BH, Grulke EA. Nanoceria biodistribution and retention in the rat after its intravenous administration are not greatly influenced by dosing schedule, dose, or particle shape. *Environ-Sci Nano*. Dec 2014;1(6):549-560.
- **4.** Heckman KL, DeCoteau W, Estevez A, et al. Custom cerium oxide nanoparticles protect against a free radical mediated autoimmune degenerative disease in the brain. *ACS Nano*. Dec 23 2013;7(12):10582-10596.
- **5.** Dan M, Wu P, Grulke EA, Graham UM, Unrine JM, Yokel RA. Ceria-engineered nanomaterial distribution in, and clearance from, blood: size matters. *Nanomedicine (Lond)*. Jan 2012;7(1):95-110.
- Yokel RA, Florence RL, Unrine JM, et al. Biodistribution and oxidative stress effects of a systemically-introduced commercial ceria engineered nanomaterial. *Nanotoxicology*. 2009;3(3):234-248.
- **7.** Konduru NV, Jimenez RJ, Swami A, et al. Silica coating influences the corona and biokinetics of cerium oxide nanoparticles. *Particle and Fibre Toxicology*. Oct 12 2015;12.
- Hardas SS, Butterfield DA, Sultana R, et al. Brain distribution and toxicological evaluation of a systemically delivered engineered nanoscale ceria. *Toxicological sciences*. Aug 2010;116(2):562-576.
- **9.** Yokel RA, Au TC, MacPhail R, et al. Distribution, elimination, and biopersistence to 90 days of a systemically introduced 30 nm ceria-engineered nanomaterial in rats. *Toxicological Sciences.* May 2012;127(1):256-268.
- **10.** Li D, Morishita M, Wagner JG, et al. In vivo biodistribution and physiologically based pharmacokinetic modeling of inhaled fresh and aged cerium oxide nanoparticles in rats. *Particle and Fibre Toxicology*. 2016;13(1):45.
- **11.** Geraets L, Oomen AG, Krystek P, et al. Tissue distribution and elimination after oral and intravenous administration of different titanium dioxide nanoparticles in rats. *Particle and Fibre Toxicology*. 2014;11:30.
- **12.** He X, Zhang H, Ma Y, et al. Lung deposition and extrapulmonary translocation of nano-ceria after intratracheal instillation. *Nanotechnology*. Jul 16 2010;21(28):285103.
- **13.** Molina RM, Konduru NV, Jimenez RJ, et al. Bioavailability, distribution and clearance of tracheally instilled, gavaged or injected cerium dioxide nanoparticles and ionic cerium. *Environ-Sci Nano.* Dec 2014;1(6):561-573.
- **14.** Kumari M, Kumari SI, Grover P. Genotoxicity analysis of cerium oxide micro and nanoparticles in Wistar rats after 28 days of repeated oral administration. *Mutagenesis.* Nov 2014;29(6):467-479.
- **15.** Kumari M, Kumari SI, Kamal SSK, Grover P. Genotoxicity assessment of cerium oxide nanoparticles in female Wistar rats after acute oral exposure. *Mutat Res-Gen Tox En.* Dec 2014;775:7-19.
- **16.** Konduru NV, Murdaugh KM, Sotiriou GA, et al. Bioavailability, distribution and clearance of tracheally-instilled and gavaged uncoated or silica-coated zinc oxide nanoparticles. *Particle and fibre toxicology.* 2014;11:44.
- **17.** Park EJ, Park YK, Park K. Acute toxicity and tissue distribution of cerium oxide nanoparticles by a single oral administration in rats *Toxicological Research KSOT*. 2009;25(2):79-84